Myimmune
1 known investors
MyImmune develops AI that analyzes adaptive immune repertoire data to identify drug targets, predict patient responses to immunotherapies, and build biomarkers and companion diagnostics. It serves biotech, pharma, and CRO customers working in oncology, autoimmune, and infectious diseases.
Investors · 1
Competitors · 7
by search overlap
Immunai12 shared keywordsImmunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.
Infinimmune10 shared keywordsInfinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.
Immune-Onc Therapeutics9 shared keywordsImmune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
Inimmune9 shared keywordsInimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.
Immunome7 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Inmune Bio7 shared keywordsINmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
Immunitoai5 shared keywordsImmunito AI is an in-silico antibody discovery company that combines artificial intelligence with an in-house biological lab to speed up and improve the discovery of antibodies. It serves the biotech and biopharmaceutical industry.
Companies competing with Myimmune for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Myimmune do?
- MyImmune develops AI that analyzes adaptive immune repertoire data to identify drug targets, predict patient responses to immunotherapies, and build biomarkers and companion diagnostics. It serves biotech, pharma, and CRO customers working in oncology, autoimmune, and infectious diseases.
- Who are Myimmune's investors?
- Myimmune's investors include OSAKA University Venture Capital.